EP Patent

EP2845592A1 — Benzoxazepin PI3K inhibitor compounds and methods of use

Assigned to F Hoffmann La Roche AG · Expires 2015-03-11 · 11y expired

What this patent protects

The invention relates to benzoxazepin compounds of Formula I including stereoisomers, geometric isomers, tautomers, or pharmaceutically acceptable salts thereof, wherein: Z 1 is CR 1 or N; Z 2 is CR 2 or N; Z 3 is CR 3 or N; Z 4 is CR 4 or N; and B is a pyrazolyl, i…

USPTO Abstract

The invention relates to benzoxazepin compounds of Formula I including stereoisomers, geometric isomers, tautomers, or pharmaceutically acceptable salts thereof, wherein: Z 1 is CR 1 or N; Z 2 is CR 2 or N; Z 3 is CR 3 or N; Z 4 is CR 4 or N; and B is a pyrazolyl, imidazolyl, or triazolyl ring which compounds have anti-cancer activity, and more specifically, inhibit PI3 kinase activity.

Drugs covered by this patent

Patent Metadata

Patent number
EP2845592A1
Jurisdiction
EP
Classification
—
Expires
2015-03-11
Drug substance claim
No
Drug product claim
No
Assignee
F Hoffmann La Roche AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.